| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 111.48 | 3.6% |
| Total Income | 111.85 | 3.9% |
| Expenditure | 94.83 | 2.6% |
| PBT | 17.03 | 10.7% |
| Net Profit | 11.92 | 17.7% |
| OPM | 21.69% | 0.69pp |
| NPM | 10.66% | 1.78pp |
| EPS | 11.49 | 17.6% |
Kwality Pharmaceuticals Reports 39.8% YoY Revenue Growth in Q1 FY26, Eyes X500 Crore Revenue Target
11 Aug 2025 · 11 Aug 2025, 02:15 pm
Summary
Kwality Pharmaceuticals reported a 39.8% YoY increase in revenue for Q1 FY26, reaching X111.8 crore. This growth was primarily due to increased sales of registered products across key international markets. EBITDA grew 39% YoY to X24.6 crore, and net profit rose 43% to X11.9 crore. The company successfully completed a regulatory audit in Zimbabwe and participated in the Pharma Expo in Kenya. Kwality Pharmaceuticals is preparing for the EU-GMP audit for its general and beta-lactam manufacturing facilities in October, and for the WHO-GMP inspection of its biologics facility later this year. The company is also expanding production capacity for its first biological product, Erythropoietin (EPO).
Key Highlights
- 1
39.8% YoY revenue growth in Q1 FY26
- 2
EBITDA grew 39% YoY to X24.6 crore
- 3
Net profit rose 43% to X11.9 crore
- 4
Successfully completed a regulatory audit in Zimbabwe
- 5
Participated in the Pharma Expo in Kenya
- 6
Preparing for the EU-GMP audit in October
- 7
WHO-GMP inspection of biologics facility later this year
- 8
Expanding production capacity for Erythropoietin (EPO)
Management Comments
Management of Kwality Pharmaceuticals
Kwality Pharmaceutical Ltd reported a strong start to FY26, with consolidated revenue rising 39.8% year-on-year. This growth was driven primarily by increased sales of registered products across key international markets. EBITDA grew 39% YoY, from X17.6 crore to X24.6 crore. EBITDA margins remained stable at around 22%, indicating operational efficiency despite scale-up. Net profit rose sharply by 43%, from 8.3 crore to X11.9 crore, aided by improved scale up.
Informational and educational content only. Not investment advice.